NCT01026831已完成3 期
A Phase III, Randomized, Active Comparator-Controlled, Twelve-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma and Ocular Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 643
- 主要终点
- Mean Intraocular Pressure (IOP) Change From Baseline at All 9 Time Points During the Study (0800, 1000 and 1600 Hrs at Weeks 2, 6, and 12)
研究概览
简要总结
This study was to compare the safety and efficacy of the preservative-free formulation of 0.0015% MK2452 (tafluprost) and preservative-free 0.5% timolol maleate in patients with open-angle glaucoma and ocular hypertension. This study was to demonstrate that the preservative-free formulation of 0.0015% tafluprost is non-inferior to preservative-free 0.5% timolol maleate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has been diagnosed with primary open-angle glaucoma, pigmentary glaucoma, capsular glaucoma/pseudoexfoliation, or ocular hypertension
- •Patient has a mean (or median) IOP of >=23 and =<36 in at least one eye at the 0800 hours time point at the Baseline Visit.
- •Patient has <5 mmHg difference in mean (or median) IOP between eyes at each time point (0800 hours, 1000 hours, and 1600 hours) at Baseline.
- •Patient is currently using a prescribed ocular hypotensive medication and has been on a stable dose for 30 days prior to screening, or patient is drug-naive (those who have never used or who have not used ocular hypotensive medication for at least 4 weeks prior to screening)
- •Patient is able to safely discontinue current ocular hypotensive medication during up to the 4-week washout period
- •Patient has vision corrected to 20/80 or better in each eye
- •Patient is willing and able to avoid wearing contact lenses from 4 weeks prior to dosing through 24 hour after final dosing
- •Patient is willing and able to self-administer or has an able person available on a daily basis to assist with administration of study medications
- •Patient is not pregnant and not planning to become pregnant during the study
- •Patient is male or female ≥18 of age on the day of signing the informed consent
排除标准
- •Patient is unable to use study medication in the affected eye(s)
- •Patient has a history of inflammatory ocular surface disease or anterior or posterior uveitis in either eye
- •Patient has a history of retinal detachment, diabetic retinopathy, or other progressive retinal disease
- •Patient has experienced significant visual field loss within the last year
- •Patient has had intraocular surgery in either eye in the last 4 months
- •Patient has a history of glaucoma surgery or refractive surgery in either eye
- •Patient is currently taking two or more anti-glaucoma medications (except Cosopt™ or its generic formulation)
- •Patient has previously used tafluprost
- •Patient has a history of cardiovascular disorder within 6 months prior to screening
- •Patient has a history of bronchial asthma, wheezing, pneumonia, COPD, other pulmonary disease, or abnormal chest x-ray
- •Patient has a mean (or median) IOP >36 mmHg in either eye at the Screening Visit or at any time point (0800 hours, 1000 hours, and 1600 hours) of the Baseline Visit.
研究组 & 干预措施
Tafluprost
Experimental
Preservative-free tafluprost
干预措施: Preservative-Free Tafluprost (Drug)
结局指标
主要结局
Mean Intraocular Pressure (IOP) Change From Baseline at All 9 Time Points During the Study (0800, 1000 and 1600 Hrs at Weeks 2, 6, and 12)
时间窗: Baseline, Weeks 2, 6, and 12.
IOP was measured using a Goldmann applanation tonometer. The primary evaluation was based on the study eye (the worse eye based on the 0800 hour IOP baseline or the right eye when both eyes had the same IOP). IOP change from baseline was calculated using the baseline IOP at each time point (0800 hours at baseline to 0800 hours at Week 2, 6, and 12; 1000 hours at baseline to 1000 hours at Week 2, 6, and 12; 1600 hours at baseline to 1600 hours at Week 2, 6, and 12). Lowering elevated IOP is a treatment goal of glaucoma.
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant AdministrationsOcular HypertensionOpen-angle GlaucomaNCT01306461Santen Oy401
进行中（未招募）
1 期
A clinical study with a Factor VIIa (Recombinant) to evaluate its efficacy, its safety and its behaviour in human blood in pediatric patients from birth to less than 12 years of age with Hemophilia A or B with inhibitors to factor VIII or IXCongenital Hemophilia A or B patients with inhibitors to Factor VIII or Factor IXMedDRA version: 19.1Level: PTClassification code 10056492Term: Haemophilia A with anti factor VIIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 19.1Level: PTClassification code 10056494Term: Haemophilia B with anti factor IXSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-000958-38-CZFB USA, Inc.24
进行中（未招募）
1 期
A clinical study with a Factor VIIa (Recombinant) to evaluate its efficacy, its safety and its behaviour in human blood in pediatric patients from birth to less than 12 years of age with Hemophilia A or B with inhibitors to factor VIII or IXEUCTR2015-000958-38-BGFB USA, Inc.24
进行中（未招募）
1 期
A clinical study with a Factor VIIa (Recombinant) to evaluate its efficacy, its safety and its behaviour in human blood in pediatric patients from birth to less than 12 years of age with Hemophilia A or B with inhibitors to factor VIII or IXCongenital Hemophilia A or B with inhibitors to Factor VIII or Factor IXMedDRA version: 20.0Level: PTClassification code 10056492Term: Haemophilia A with anti factor VIIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: PTClassification code 10056494Term: Haemophilia B with anti factor IXSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-000958-38-ITFB USA, INC.25
进行中（未招募）
1 期
A clinical study with a Factor VIIa (Recombinant) to evaluate its efficacy, its safety and its behaviour in human blood in patients with Hemophilia A or B with inhibitors to factor VIII or IXCongenital haemophilia A or B patients with inhitors to Factor VIII or Factor IXMedDRA version: 17.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850MedDRA version: 17.0Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)System Organ Class: 100000004850EUCTR2013-004779-11-ROrEVO Biologics, Inc.27